Remarks on the Causality, Unitarity and Supersymmetric Extension of the Lorentz and CPT-Violating Maxwell-Chern-Simons Model

The gauge-invariant Chern-Simons-type Lorentz- and CPT-breaking term is here re-assessed and issues like causality, unitarity, spontaneous gauge-symmetry breaking are investigated. Moreover, we obtain a minimal extension of such a system to a supersymmetric environment. We comment on resulting peculiar self-couplings for the gauge sector, as well as on background contribution for gaugino masses.Comment: 5 pages, NPB style, talk presented at "Renormalization Group and Anomalies in Gravity and Cosmology", Ouro Preto, Brazil, March 200

Efficacy of Dexrazoxane in Preventing Anthracycline Cardiotoxicity in Breast Cancer

Abstract Objectives The authors performed a systematic review and meta-analysis of randomized and nonrandomized trials on the efficacy of dexrazoxane in patients with breast cancer who were treated with anthracyclines with or without trastuzumab. Background Breast cancer treatment with anthracyclines and trastuzumab is associated with an increased risk of cardiotoxicity. Among the various strategies to reduce the risk of cardiotoxicity, dexrazoxane is an option for primary prevention, but it is seldom used in clinical practice. Methods Online databases were searched from January 1990 up to March 1, 2019, for clinical trials on the use of dexrazoxane for the prevention of cardiotoxicity in patients with breast cancer receiving anthracyclines with or without trastuzumab. Risk ratios (RRs) with 95% confidence intervals (CIs) were calculated using a random-effects model meta-analysis. Results Seven randomized trials and 2 retrospective trials with a total of 2,177 patients were included. Dexrazoxane reduced the risk of clinical heart failure (RR: 0.19; 95% CI: 0.09 to 0.40; p Conclusions Dexrazoxane reduced the risk of clinical heart failure and cardiac events in patients with breast cancer undergoing anthracycline chemotherapy with or without trastuzumab and did not significantly impact cancer outcomes. However, the quality of available evidence is low, and further randomized trials are warranted before the systematic implementation of this therapy in clinical practice

Scaling critical behavior of superconductors at zero magnetic field

We consider the scaling behavior in the critical domain of superconductors at zero external magnetic field. The first part of the paper is concerned with the Ginzburg-Landau model in the zero magnetic field Meissner phase. We discuss the scaling behavior of the superfluid density and we give an alternative proof of Josephson's relation for a charged superfluid. This proof is obtained as a consequence of an exact renormalization group equation for the photon mass. We obtain Josephson's relation directly in the form $\rho_{s}\sim t^{\nu}$, that is, we do not need to assume that the hyperscaling relation holds. Next, we give an interpretation of a recent experiment performed in thin films of $YBa_{2}Cu_{3}O_{7-\delta}$. We argue that the measured mean field like behavior of the penetration depth exponent $\nu'$ is possibly associated with a non-trivial critical behavior and we predict the exponents $\nu=1$ and $\alpha=-1$ for the correlation lenght and specific heat, respectively. In the second part of the paper we discuss the scaling behavior in the continuum dual Ginzburg-Landau model. After reviewing lattice duality in the Ginzburg-Landau model, we discuss the continuum dual version by considering a family of scalings characterized by a parameter $\zeta$ introduced such that $m_{h,0}^2\sim t^{\zeta}$, where $m_{h,0}$ is the bare mass of the magnetic induction field. We discuss the difficulties in identifying the renormalized magnetic induction mass with the photon mass. We show that the only way to have a critical regime with $\nu'=\nu\approx 2/3$ is having $\zeta\approx 4/3$, that is, with $m_{h,0}$ having the scaling behavior of the renormalized photon mass.Comment: RevTex, 15 pages, no figures; the subsection III-C has been removed due to a mistak

Dietary supplementation with hydrolyzed yeast and its effect on the performance, intestinal microbiota, and immune response of weaned piglets.

The objective of this study was to evaluate the effects of autolyzed yeast on performance, cecal microbiota, and leukogram of weaned piglets. A total of 96 piglets of commercial line weaned at 21-day-old were used. The experimental design was a randomized block design with four treatments (diets containing 0.0%, 0.3%, 0.6%, and 0.9% autolyzed yeast), eight replicates, and three animals per pen in order to evaluate daily weight gain, daily feed intake, and feed conversion in periods of 0 to 15, 0 to 26, and 0 to 36 days. Quadratic effects of autolyzed yeast inclusion were observed on the feed conversion from 0 to 15 days, on daily weight gain from 0 to 15 days, 0 to 26 days and, 0 to 36 days, indicating an autolyzed yeast optimal inclusion level between 0.4% and 0.5%. No effect from autolyzed yeast addition was observed on piglet daily feed intake, cecal microbiota, and leukogram; however, i.m. application of E. coli lipopolysaccharide reduced the values of total leukocytes and their fractions (neutrophils, eosinophils, lymphocytes, monocytes, and rods). Therefore, autolyzed yeast when provided at levels between 0.4% and 0.5% improved weaned piglets’ performance.info:eu-repo/semantics/publishedVersio